Desired vancomycin trough serum concentration for treating invasive methicillin-resistant staphylococcal infections

Pediatric Infectious Disease Journal

Volumn 32, Issue 10, 2013, Pages 1077-1079

  Frymoyer, Adam ^a   Guglielmo, B Joseph ^b   Hersh, Adam L ^c  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Children; Methicillin resistant Staphylococcus aureus; Pharmacokinetics; Vancomycin

Indexed keywords

VANCOMYCIN;

AREA UNDER THE CURVE; CASE REPORT; CHILD; CONFERENCE PAPER; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; SIMULATION; STEADY STATE;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BODY WEIGHT; CHILD; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84891836161     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318299f75c     Document Type: Conference Paper

References (15)

1. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52: 285-292.
2. Frymoyer A, Hersh AL, Benet LZ, et al. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009;28: 398-402.
3. Frymoyer A, Hersh AL, Coralic Z, et al. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation. Clin Ther. 2010;32: 534-542.
4. Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43: 925-942.
5. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49: 325-327.
6. Frymoyer A, Guglielmo BJ, Wilson SD, et al. Impact of a hospital wide increase in empiric pediatric vancomycin dosing on initial trough concentrations. Pharmacotherapy. 2011;31: 871-876.
7. Eiland LS, English TM, Eiland EH 3rd. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother. 2011;45: 582-589.
8. Chhim RF, Arnold SR, Lee KR. Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children with suspected invasive staphylococcal infections. J Ped Infect Dis. 2012. Available at: http://jpids.oxfordjournals.org/content/early/2012/09/10/jpids.pis083. Accessed November 14, 2012.
9. Gordon CL, Thompson C, Carapetis JR, et al. Trough concentrations of vancomycin: adult therapeutic targets are not appropriate for children. Pediatr Infect Dis J. 2012;31: 1269-1271.
10. Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J. 1995;14: 667-673.
11. Lamarre P, Lebel D, Ducharme MP. A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population. Antimicrob Agents Chemother. 2000;44: 278-282.
12. Wrishko RE, Levine M, Khoo D, et al. Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients. Ther Drug Monit. 2000;22: 522-531.
13. Gerber JS, Coffin SE, Smathers SA, et al. Trends in the incidence of methicillin- resistant Staphylococcus aureus infection in children's hospitals in the United States. Clin Infect Dis. 2009;49: 65-71.
14. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57: 734-744.
15. Lodise TP, Lomaestro B, Graves J, et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52: 1330-1336.